Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Aticaprant in Healthy Japanese Males
NCT04791332Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2021
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of aticaprant in major depressive disorder (MDD) and anhedonia ((none)) (2 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants with Adverse Events up to 5 weeks and Plasma Concentration of JNJ-67953964. Started Apr 2021; status: completed.
02
Drugs
aticaprant
03
Conditions
major depressive disorder (MDD)anhedonia ((none))
Beyond the preview
Go deeper on NCT04791332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04791332.